Denali Therapeutics (DNLI) Invested Capital (2022 - 2025)

Denali Therapeutics (DNLI) has 3 years of Invested Capital data on file, last reported at $5.6 million in Q4 2025.

• On a quarterly basis, Invested Capital fell 39.89% year-over-year to $5.6 million in Q4 2025; TTM through Mar 2026 was $18.2 million, a 22.59% decrease from a year earlier, with the FY2025 full-year figure at $5.6 million, down 39.89% from the prior year.
• Invested Capital for Q4 2025 stood at $5.6 million, roughly flat from $5.6 million in the prior quarter.
• Over the last five years, Invested Capital for DNLI reached as high as $9.3 million in Q4 2024 and fell as low as $1.4 million in Q3 2022.
• Historically, Invested Capital has averaged $5.6 million across 3 years, with a median of $5.6 million in 2025.
• On a YoY basis, Invested Capital climbed as much as 0.92% in 2025 and fell as far as 39.89% in 2025.
• Year by year, Invested Capital stood at $4.4 million in 2022, then soared by 112.88% to $9.3 million in 2024, then plunged by 39.89% to $5.6 million in 2025.
• Per Business Quant data, the three most recent Invested Capital figures were $5.6 million in Q4 2025, $5.6 million in Q3 2025, and $7.0 million in Q2 2025.